124 related articles for article (PubMed ID: 16125780)
1. Rifaximin--the promising anti-microbial for enteric infections.
Arya SC; Agarwal N
J Infect; 2005 Oct; 51(3):262. PubMed ID: 16125780
[No Abstract] [Full Text] [Related]
2. In vitro antimicrobial activity of rifaximin against enteropathogens causing traveler's diarrhea.
Ruiz J; Mensa L; O'Callaghan C; Pons MJ; González A; Vila J; Gascón J
Diagn Microbiol Infect Dis; 2007 Dec; 59(4):473-5. PubMed ID: 17889485
[TBL] [Abstract][Full Text] [Related]
3. Rifaximin--a novel antimicrobial for enteric infections.
Huang DB; DuPont HL
J Infect; 2005 Feb; 50(2):97-106. PubMed ID: 15667909
[TBL] [Abstract][Full Text] [Related]
4. Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy.
Infante RM; Ericsson CD; Jiang ZD; Ke S; Steffen R; Riopel L; Sack DA; DuPont HL
Clin Gastroenterol Hepatol; 2004 Feb; 2(2):135-8. PubMed ID: 15017618
[TBL] [Abstract][Full Text] [Related]
5. [The use of Rifaximin in daily clinical practice].
Bajor J
Orv Hetil; 2006 Jan; 147(3):139-40. PubMed ID: 16515033
[No Abstract] [Full Text] [Related]
6. Rifaximin (Xifaxan) for travelers' diarrhea.
Med Lett Drugs Ther; 2004 Sep; 46(1191):74-5. PubMed ID: 15365508
[No Abstract] [Full Text] [Related]
7. Rifaximin (Xifaxan) for traveler's diarrhea.
Keenum AJ; Stockton MD
Am Fam Physician; 2005 Dec; 72(12):2525-6. PubMed ID: 16370411
[No Abstract] [Full Text] [Related]
8. Antimicrobial Susceptibility of Staphylococcus Isolates from the Skin of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Treated with Repeat Courses of Rifaximin.
DuPont HL; Wolf RA; Israel RJ; Pimentel M
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795384
[No Abstract] [Full Text] [Related]
9. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea.
Taylor DN; Bourgeois AL; Ericsson CD; Steffen R; Jiang ZD; Halpern J; Haake R; Dupont HL
Am J Trop Med Hyg; 2006 Jun; 74(6):1060-6. PubMed ID: 16760520
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity and fecal concentration of rifaximin after oral administration.
Jiang ZD; Ke S; Palazzini E; Riopel L; Dupont H
Antimicrob Agents Chemother; 2000 Aug; 44(8):2205-6. PubMed ID: 10898704
[TBL] [Abstract][Full Text] [Related]
11. Rifaximin: a new approach to the treatment of travelers' diarrhea. Conclusion.
Ericsson CD
J Travel Med; 2001 Dec; 8(Suppl 2):S40. PubMed ID: 12186673
[No Abstract] [Full Text] [Related]
12. Rifaximin: a new approach to the treatment of travelers' diarrhea. Introduction.
Ericsson CD
J Travel Med; 2001 Dec; 8(Suppl 2):S25. PubMed ID: 12186669
[No Abstract] [Full Text] [Related]
13. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci.
DuPont HL; Jiang ZD
Clin Microbiol Infect; 2004 Nov; 10(11):1009-11. PubMed ID: 15522005
[TBL] [Abstract][Full Text] [Related]
14. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections.
Gerard L; Garey KW; DuPont HL
Expert Rev Anti Infect Ther; 2005 Apr; 3(2):201-11. PubMed ID: 15918778
[TBL] [Abstract][Full Text] [Related]
15. Current concepts in travelers' diarrhea: epidemiology, antimicrobial resistance and treatment.
Okhuysen PC
Curr Opin Infect Dis; 2005 Dec; 18(6):522-6. PubMed ID: 16258326
[TBL] [Abstract][Full Text] [Related]
16. Rifaximin: a nonabsorbed antimicrobial as a new tool for treatment of travelers' diarrhea.
Steffen R
J Travel Med; 2001 Dec; 8(Suppl 2):S34-9. PubMed ID: 12186672
[No Abstract] [Full Text] [Related]
17. Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone.
Dupont HL; Jiang ZD; Belkind-Gerson J; Okhuysen PC; Ericsson CD; Ke S; Huang DB; Dupont MW; Adachi JA; De La Cabada FJ; Taylor DN; Jaini S; Martinez Sandoval F
Clin Gastroenterol Hepatol; 2007 Apr; 5(4):451-6. PubMed ID: 17382603
[TBL] [Abstract][Full Text] [Related]
18. [Bacterially induced traveler's diarrhea. Local antibiosis effective without systemic effects].
MMW Fortschr Med; 2008 Nov; 150(45):48-9. PubMed ID: 19058391
[No Abstract] [Full Text] [Related]
19. Efficacy of rifaximin and vancomycin combination therapy in a patient with refractory Clostridium difficile-associated diarrhea.
Berman AL
J Clin Gastroenterol; 2007; 41(10):932-3. PubMed ID: 18090164
[No Abstract] [Full Text] [Related]
20. Enteroaggregative Escherichia coli as a cause of traveler's diarrhea: clinical response to ciprofloxacin.
Glandt M; Adachi JA; Mathewson JJ; Jiang ZD; DiCesare D; Ashley D; Ericsson CD; DuPont HL
Clin Infect Dis; 1999 Aug; 29(2):335-8. PubMed ID: 10476738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
